Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Michael P Manns" Clear advanced filters

  • Although several antiviral treatments for HBV infection have recently reached the market, no direct acting antiviral drugs to treat infection with HCV have been licensed in the 20 years since its identification. Excitingly, recent publications herald several small revolutions in antiviral treatment of HCV that have considerable relevance for prospective HCV therapies.

    • Sandra Ciesek
    • Michael P. Manns
    News & Views
    Nature Reviews Gastroenterology & Hepatology
    Volume: 8, P: 69-71

  • It has been 25 years since the hepatitis C virus (HCV) was discovered. Now, pipelines are bristling with exciting new direct-acting antiviral drugs, many of which are in late-stage clinical trials. In this Review, Manns and von Hahn examine the future of anti-HCV therapy, the prospect of all-oral interferon-free treatment regimens, and discuss the key challenges faced by clinicians and drug developers.

    • Michael P. Manns
    • Thomas von Hahn
    Reviews
    Nature Reviews Drug Discovery
    Volume: 12, P: 595-610

  • Insights into the life cycle of hepatitis C virus (HCV) have facilitated the development of a number of innovative agents. Here, Manns and colleagues discuss the obstacles in current HCV management, the key challenges for new HCV antivirals and potential future therapeutic options.

    • Michael P. Manns
    • Graham R. Foster
    • Michael Houghton
    Reviews
    Nature Reviews Drug Discovery
    Volume: 6, P: 991-1000

  • Hepatitis D is considered to be the most severe form of viral hepatitis in humans and represents a major health burden in certain areas of the world. Diagnosis is challenging and treatment options are limited. This Review discusses the epidemiology, virology, pathogenesis, diagnosis and management of hepatitis D and highlights future challenges.

    • Heiner Wedemeyer
    • Michael P. Manns
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 7, P: 31-40